Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Mouth Neoplasms 1Mouth Diseases 1Lichen Planus, Oral 1Leukoplakia, Oral 1Keratosis, Actinic 1Graft vs Host Disease 1Glioma 1Actinic cheilitis 1

Interventions

Magnetic Resonance Spectroscopy 19Temozolomide 16Radiotherapy 10Specimen Handling 7Blood Specimen Collection 7Radiation 6Bevacizumab 5Nivolumab 4Cyclophosphamide 4Biopsy 4vorasidenib 3trametinib 3pembrolizumab 3olaparib 3fludarabine 3dabrafenib 3Watchful Waiting 3Surgical Procedures, Operative 3Magnetic Resonance Imaging 3Drug Therapy 3olutasidenib 2lutetium Lu 177 dotatate 2fluorodopa F 18 2fluciclovine F-18 2entrectinib 2contrast agent BR1 2Restraint, Physical 2Radiosurgery 2Microdialysis 2Flucytosine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Glioma × Tomography, Optical Coherence × Clear all
NCT05859334 2026-06-02

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡